Navigation Links
Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
Date:3/7/2013

Norwood, MA (PRWEB) March 07, 2013

As we get closer to the American College of Cardiology (ACC) meeting 9-11 March, BioPharm Insight has put together a snapshot of forward-looking cardiovascular (CV) disease coverage. To view the full report, start a free trial today.

CV-related diseases are the number one cause of death globally, with an estimated incidence rate of 17.3 million people, according to World Health Organization (WHO) 2008 statistics. Besides antiplatelets and antithrombotic therapies, oral anticoagulants have been prescribed to prevent CV disease, replacing the cumbersome standard-of-care, warfarin.

In January 2013, BioPharm Insight reported that Daiichi Sankyo's Phase III Lixiana (edoxaban) stroke prevention drug is not viewed as differentiated enough from already-approved drugs such as Boehringer Ingelheim's Pradaxa (dabigatran), Bayer/Johnson & Johnson's Xarelto (rivaroxaban) and Bristol-Myers Squibb/Pfizer's Eliquis (apixaban).

WHO's data shows 7.5 million deaths, or 13% of all CV-related deaths, can be attributed to raised blood pressure. Of those 7.5 million deaths, 51% are due to stroke and 45% are due to coronary heart disease. Cholesterol accumulation in blood vessels is a major risk factor for stroke and heart disease.

On 14 December 2012, BioPharm Insight reported that Merck's Vytorin (simvastin/ezetimibe) and Zetia (ezetimibe) cholesterol drug sales could be negatively impacted should the IMPROVE-IT CV outcomes trial for Vytorin fail to demonstrate a significant reduction in events. Experts also believe that due to the recent failure of the HPS2-THRIVE outcomes trial of Merck's "good" cholesterol-raising (HDL) drug Tredaptive, the FDA
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
2. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
3. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
6. CeNeRx BioPharma Completes $4.85 Million Financing
7. PDL BioPharma Completes Regular Quarterly Dividend Payment
8. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
11. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)...   SurePure, Inc . (OTCQB: SURP), a ... the Company has completed the verification process and ... ("SURP") securities on OTCQB, an electronic quote and ... stage companies. On March 26, 2014, ... designed to improve marketplace integrity and enhance transparency ...
(Date:3/27/2015)... 27, 2015 WuXi PharmaTech (Cayman) Inc. ... capability and technology platform company serving the global ... that an Investigational New Drug (IND) application for ... arthritis has been accepted for review by the ... In September 2012, MedImmune, the global biologics ...
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... CO (PRWEB) March 26, 2015 The ... has formed a strategic alliance with Designing Gig LLC ... their clients. , “Forging this alliance with ... Now we can extend a comprehensive, end-to-end, digital ... development, strategy, and execution,” said Chuck Miller, president of ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2
... , PURCHASE, N.Y., Oct. 15 Nutrition 21, Inc. ... nutritional supplements under the Iceland Health®, Chromax® and Diabetes ... improve cardiovascular health, enhance memory and reduce chronic joint ... and the full fiscal year ended June 30, 2009. ...
... MedImmune today announced that researchers will present data on ... the American College of Rheumatology, from October 17 to ... Pennsylvania. , "Through our research into novel disease ... our mission of using scientific excellence to deliver life-changing ...
... Today, Formatech, Inc. announced that GeoVax Labs, Inc.,s ... the first clinical candidate that is formulated and filled under ... be completed in January 2010. Under this program, Formatech ... one lot of the vaccine for use in support of ...
Cached Biology Technology:Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 2Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 3Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 4Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 5Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 6MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 2Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 4
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... NEW YORK , March 17, 2015 /PRNewswire/ ... , the largest exhibition for service robots ever ... . RoboUniverse takes place on May 11-13, 2015 ... Sponsors and exhibitors for the event include: Acorn ... Motion Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic ...
(Date:3/12/2015)... Calif. , March 12, 2015 WHEN:Tuesday, ... Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , ... Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... order to compete in several different markets and ... is currently witnessing an uptrend. ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... President Barack Obama called for in his address to the ... other companies be responsible to both their shareholders and society, ... School of Business. The rigorous survey-based nationwide study ... Gulf of Mexico found that Republicans, Democrats and Independents strongly ...
... Researchers at the University of Cincinnati have received a ... influenza virus. An interdisciplinary team of scientists has ... Institute for Allergy and Infectious Diseases, one of the ... grant is "Glycan Receptor Mimics for Rapid Detection, Typing, ...
... WASHINGTON, DC (June 15, 2010) Today, the ... the Secretary,s Advisory Committee on Genetics, Health and Society ... anticipation of advances in sequencing and its incorporation into ... for the Committee,s consideration. "In the next ...
Cached Biology News:Consumer responses to Gulf oil spill reflect Americans' changing corporate expectations 2Team of UC scientists awarded $2 million NIH grant for better flu diagnoses 2AMP commends SACGHS whole genome sequencing focus, raises ethical questions and forms working group 2AMP commends SACGHS whole genome sequencing focus, raises ethical questions and forms working group 3
... leader in electroporation products and specialty electrodes, ... line for experiment optimization and large volume ... breakthrough in Molecular Delivery. The days of ... typically limited the number of samples and ...
... Endogens Screening Sets contain the ... develop five colorimetric sandwich ELISA plates ... in 100 l/well of cell culture ... and Detection Antibodies, Recombinant Standard (5 ...
... Competitor Assay Kits are ideal for ... binding compounds using fluorescence polarization (FP). ... of glutathione transferase to the ligand ... [PR-LBD(GST)] and a proprietary, fluorescently tagged ...
... The organic acid analysis standard ... six organic salts; molecular weights ... This standard is provided for ... column and the organic acid ...
Biology Products: